Agents in Development for Anxiety Disorders

No abstract is available for this paper.

• Publication year

  2000

• Venue

  CNS Drugs

• Publication date

  2000-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.2165/00023210-200013060-00004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• 招聘講演 Selective Serotonin Reuptake Inhibitors (SSRIs) in Panic Disorder

  2000cited by this paper
• Peptide receptors as targets for anxiolytic drugs

  2000cited by this paper
• erratum: Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes

  2000cited by this paper
• Differential EEG effects of the anxiolytic drugs, deramciclane (EGIS-3886), ritanserin and chlordiazepoxide in rats

  1999cited by this paper
• Fluvoxamine in childhood OCD: Long-term treatment

  1999cited by this paper
• Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder.

  1999cited by this paper
• Effects of mCPP on the Extracellular Concentrations of Serotonin and Dopamine in Rat Brain

  1999cited by this paper
• Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders.

  1999cited by this paper
• Quality of life in patients with panic disorder.

  1999cited by this paper
• An update on GABAA receptors.

  1999cited by this paper
• Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?

  1999cited by this paper
• Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain.

  1999cited by this paper
• Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder.

  1999cited by this paper
• Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders.

  1999cited by this paper
• Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes

  1999cited by this paper
• Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.

  1999cited by this paper
• Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action.

  1999cited by this paper
• Prevention by 5-HT1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat.

  1999cited by this paper
• Treatment of social phobia with gabapentin: a placebo-controlled study.

  1999cited by this paper
• N-methyl-D-aspartate (NMDA)-mediated corticotropin-releasing factor (CRF) release in cultured rat amygdala neurons.

  1999cited by this paper
• Neuropsychopharmacological properties of neuroactive steroids.

  1999cited by this paper
• Olanzapine added to fluoxetine in unresponsive obsessive-compulsive disorder

  1999cited by this paper
• Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders.

  1999cited by this paper
• The neurosteroids DHEA and DHEAS may influence cognitive performance by altering affective state.

  1999cited by this paper
• Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety.

  1999cited by this paper
• Anxiolytic-like action of neurokinin substance P administered systemically or into the nucleus basalis magnocellularis region.

  1998cited by this paper
• The novel buspirone analogue, 8-[4-[2-(1,2,3,4-tetrahydroisoquinolinyl) [butyl]-8 -azaspiro[4.5] decane-7,9 dione, with anxiolytic-like and antidepressant-like effects in rats

  1998cited by this paper
• Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in anxiety-like behavior and unconditioned startle--effective hemisphere depends on the behavior.

  1998cited by this paper
• Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men.

  1998cited by this paper
• SSRIs in the Treatment of obsessive‐compulsive disorder

  1998cited by this paper
• Pharmacotherapy for obsessive-compulsive disorder.

  1998cited by this paper
• Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens.

  1998cited by this paper
• Role of serotonin in obsessive-compulsive disorder

  1998cited by this paper
• Plasma Neuropeptide Y (NPY) Increases in Humans in Response to the α2 Antagonist Yohimbine

  1998cited by this paper
• Brain circuits in panic disorder.

  1998cited by this paper
• Serotonergic‘vulnerability’ in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram‐responders

  1998cited by this paper
• Substance-P antagonists: a new treatment for depression?

  1998cited by this paper
• Distinct mechanism for antidepressant activity by blockade of central substance P receptors.

  1998cited by this paper
• Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses.

  1998cited by this paper
• The impact of comorbidity on the treatment of panic disorder.

  1998cited by this paper
• Abecarnil, a new beta-carboline, in the treatment of anxiety disorders

  1998cited by this paper
• NMDA receptors mediate lasting increases in anxiety-like behavior produced by the stress of predator exposure--implications for anxiety associated with posttraumatic stress disorder.

  1998cited by this paper
• Anxiolytic-like effects of PNU-101017, a partial agonist at the benzodiazepine receptor

  1997cited by this paper
• Efficacy of ondansetron in the treatment of generalized anxiety disorder

  1997cited by this paper
• Beyond attention: The role of amygdala NMDA receptors in fear conditioning

  1997cited by this paper
• Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks

  1997cited by this paper
• Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder.

  1997cited by this paper
• Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse.

  1997cited by this paper
• Dual role of 5-HT in defense and anxiety.

  1997cited by this paper
• Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls.

  1997cited by this paper
• Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial.

  1997cited by this paper
• Rapid depletion of plasma tryptophan: a review of studies and experimental methodology

  1997cited by this paper
• Buspirone potentiation of antidepressants in the treatment of PTSD

  1997cited by this paper
• A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome.

  1997cited by this paper
• Randomized, double‐blind, placebo‐controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN‐2327) in generalized anxiety

  1997cited by this paper
• Plasma neuropeptide Y in anxiety disorders: findings in panic disorder and social phobia.

  1996cited by this paper
• Cholecystokinin in anxiety.

  1996cited by this paper
• Inositol treatment of post-traumatic stress disorder.

  1996cited by this paper
• The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder.

  1996cited by this paper
• Tryptophan depletion in obsessive-compulsive patients.

  1996cited by this paper
• Serotonin, psilocybin, and body dysmorphic disorder: a case report.

  1996cited by this paper
• Elevated plasma levels of neuropeptide Y in patients with panic disorder.

  1996cited by this paper
• Ondansetron in the treatment of panic disorder.

  1996cited by this paper
• Obsessive–Compulsive Disorder

  1996cited by this paper
• Inositol treatment of obsessive-compulsive disorder.

  1996cited by this paper
• Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.

  1995cited by this paper
• A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.

  1995cited by this paper
• Future directions in anxiolytic pharmacotherapy.

  1995cited by this paper
• Venlafaxine in social phobia.

  1995cited by this paper
• Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.

  1995cited by this paper
• Behavioral and subjective effects of DN‐2327 (pazinaclone) and aiprazolam in normal volunteers

  1995cited by this paper
• Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors.

  1994cited by this paper
• Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage.

  1994cited by this paper
• Neuropeptide Y effector systems: perspectives for drug development.

  1994cited by this paper
• Combined SSRI-moclobemide treatment of psychiatric illness.

  1994cited by this paper
• Gepirone and the treatment of panic disorder: an open study.

  1993cited by this paper
• Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants.

  1993cited by this paper
• Role of the amygdala and periaqueductal gray in anxiety and panic.

  1993cited by this paper
• Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.

  1992cited by this paper
• Neurobiology of Panic Disorder.

  1991cited by this paper
• Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression.

  1991cited by this paper
• Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.

  1990cited by this paper
• Serotonin abnormalities in panic disorder

  1990cited by this paper
• Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

  1989cited by this paper
• One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites.

  1988cited by this paper
• Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo.

  1987cited by this paper
• Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder.

  1986cited by this paper
• Behavioral inhibition induced by electrical stimulation of the median raphe nucleus of the rat.

  1978cited by this paper
• Brain Specific Benzodiazepine Receptors

  1978cited by this paper
• The effects of p‐chlorophenylalanine and ethanolamine‐O‐sulphate in an animal test of anxiety

  1977cited by this paper

• Assessment of Level of Knowledge on Childbirth and Fear of Childbirth among Pregnant Women

  2019cites this paper
• Defining Childbirth Fear And Anxiety Levels In Pregnant Women

  2017cites this paper
• VIEWS OF EXPECTANT MOTHERS ABOUT SOURCES OF KNOWLEDGE AND SKILLS RELATED TO MOTHERHOOD

  2016cites this paper
• GABA and Glutamate Receptor Ligands and their Therapeutic Potential in CNS Disorders

  2010cites this paper
• Pharmacology of the GABAA Receptor

  2007cites this paper
• Pathophysiology and pharmacology of GABA(A) receptors.

  2005cites this paper
• Treatment of Anxiety and Depression in Transplant Patients

  2004cites this paper
• The benzodiazepine site of the GABAA receptor: an old target with new potential?

  2004cites this paper
• The neurobiology and control of anxious states.

  2003cites this paper
• Anxiety Disorders in Childhood and Adolescence: Basic Mechanisms and Therapeutic Interventions

  2003cites this paper
• New directions in the treatment of anxiety disorders

  2003cites this paper
• Synthesis and pharmacological evaluation of new arylpiperazines. 3-[4-[4-(3-chlorophenyl)-1-piperazinyl]butyl]-quinazolidin-4-one - a dual serotonin 5-HT(1A)/5-HT(2A) receptor ligand with an anxiolytic-like activity.

  2002cites this paper
• A new benzodiazepine pharmacology.

  2002cites this paper
• The social competition test as an animal model of anxiety in triads of male wistar rats.

  2001cites this paper
• Obsessive–Compulsive Disorder: Treatment and Treatment Resistance

  2001cites this paper
• GABA(A) receptor subtypes: dissecting their pharmacological functions.

  2001cites this paper
• GABA(A)-receptor subtypes: a new pharmacology.

  2001cites this paper
• Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

  2000cites this paper